PitchSend

Investor Presentaiton

H1 2022/23 Atos Medical impact on EBIT Atos Medical acquisition EBIT impact 33% 3% 30% 29% 0% 28% 28% 1% 0% DKK 33 million DKK 107 million DKK 60 million DKK 362 million EBIT margin Special items EBIT margin after special Atos Medical¹ H1 2022/23 items H1 2022/23 before special items Atos Medical PPA amortisation EBIT H1 2022/23 before special items & PPA amortisation Special items of DKK 33 million in H1 2022/23 related to integration costs for the Atos Medical acquisition Around 25% of the purchase value of Atos Medical is treated as intangibles, amortized over 15 years. 61 Amortisation excl. Atos Medical PPA EBITA before special items Depreciation EBITDA before special items Coloplast

View entire presentation